<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two-thirds of adults in the U.S. are overweight or <z:mp ids='MP_0001261'>obese</z:mp>, and another 26 million have type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and/or the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> have a significantly increased risk of <z:e sem="disease" ids="C0027051" disease_type="Disease or Syndrome" abbrv="MR|mi|AMI">heart attack</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> compared with people with <z:mpath ids='MPATH_458'>normal</z:mpath> insulin sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>Decreased insulin sensitivity in cardiovascular tissues as well as in traditional targets of insulin metabolic signaling, such as skeletal muscle, is an underlying abnormality in <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and T2D </plain></SENT>
<SENT sid="3" pm="."><plain>In the vasculature, insulin signaling plays a critical role in <z:mpath ids='MPATH_458'>normal</z:mpath> vascular function via endothelial cell nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> production and modulation of Ca(2+) handling and sensitivity in vascular smooth muscle cells </plain></SENT>
<SENT sid="4" pm="."><plain>Available evidence suggests that impaired vascular insulin sensitivity may be an early, perhaps principal, defect of vascular function and contributor to the pathogenesis of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> in persons with <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and T2D </plain></SENT>
<SENT sid="5" pm="."><plain>In the overweight and <z:mp ids='MP_0001261'>obese</z:mp> individual, as well as in persons with <z:hpo ids='HP_0000822'>hypertension</z:hpo>, systemic and vascular <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> often occur in concert with elevations in plasma <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Indeed, basic and clinical studies have demonstrated that <z:hpo ids='HP_0000859'>elevated plasma aldosterone</z:hpo> levels predict the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and that <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> directly interferes with insulin signaling in vascular tissues </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:hpo ids='HP_0000859'>elevated plasma aldosterone</z:hpo> levels are associated with increased <z:e sem="disease" ids="C0027051" disease_type="Disease or Syndrome" abbrv="MR|mi|AMI">heart attack</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> risk </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system and <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) antagonism reduces cardiovascular risk in these patient populations </plain></SENT>
<SENT sid="9" pm="."><plain>Recent and accumulating evidence in this area has implicated excessive Ser phosphorylation and proteosomal degradation of the docking protein, insulin receptor substrate, and enhanced signaling through hybrid insulin/IGF-1 receptor as important mechanisms underlying <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi>-mediated interruption of downstream vascular insulin signaling </plain></SENT>
<SENT sid="10" pm="."><plain>Prevention or restoration of these changes via blockade of <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> action in the vascular wall with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> <z:chebi fb="68" ids="48706">antagonists</z:chebi> (i.e., <z:chebi fb="0" ids="9241">spironolactone</z:chebi>, <z:chebi fb="0" ids="31547">eplerenone</z:chebi>) may therefore account for the clinical benefit of these compounds in <z:mp ids='MP_0001261'>obese</z:mp> and diabetic patients with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>This review will highlight recent evidence supporting the hypothesis that <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> signaling represent an ideal candidate pathway linking early promoters of <z:mp ids='MP_0002055'>diabetes</z:mp>, especially <z:e sem="disease" ids="C1257763" disease_type="Disease or Syndrome" abbrv="">overnutrition</z:e> and <z:hpo ids='HP_0001513'>obesity</z:hpo>, to vascular <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, dysfunction, and disease </plain></SENT>
</text></document>